Summary
According to the recently published report 'Cyclin Dependent Kinase 4 - Drugs In Development, 2022'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 52 molecules. Out of which approximately 49 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
The report 'Cyclin Dependent Kinase 4 - Drugs In Development, 2022' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 6, 10, 3, 15 and 7 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Undisclosed and Genetic Disorders which include indications Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor, Breast Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Mantle Cell Lymphoma, Colorectal Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Ovarian Cancer, Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Central Nervous System (CNS) Cancer, Colon Cancer, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, High-Grade Glioma, Liposarcoma, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Oligodendroglioma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Astrocytoma, Chemotherapy Induced Myelosuppression, Chronic Lymphocytic Leukemia (CLL), Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Follicular Lymphoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroblastoma, Neuroendocrine Tumors, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Small-Cell Lung Cancer, Thymic Carcinoma, Unspecified, Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chemotherapy-Induced Diarrhea (CID), Chordoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hormone Sensitive Breast Cancer, Hormone-Sensitive Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Hypopharyngeal Cancer, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Liver Cancer, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neurofibromatoses Type I (Von Recklinghausen’s Disease), Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial), Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) and Well Differentiated Liposarcoma.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Aucentra Therapeutics Pty Ltd
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
Cothera Bioscience Pty Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ESSA Pharma Inc
Fochon Pharmaceutical Ltd
G1 Therapeutics Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HEC Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Nuvation Bio Inc
Onconova Therapeutics Inc
OnQuality Pharmaceuticals LLC
Pfizer Inc
Prelude Therapeutics Inc
Qilu Regor Therapeutics Inc
Rhizen Pharmaceuticals SA
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
SATT Conectus Alsace SAS
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
SignalRx Pharmaceuticals Inc
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Tetranov International Inc
Tiziana Life Sciences Plc
Travecta Therapeutics Inc
ViroStatics SRL
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
AU-294 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AU-314 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BEBT-209 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPI-16350 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cetuximab + cobimetinib + palbociclib - Drug Profile
Product Description
Mechanism Of Action
CS-3002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dalpiciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug to Inhibit CDK4 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
ebvaciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ETH-155008 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FCN-437c - Drug Profile
Product Description
Mechanism Of Action
History of Events
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
HS-10342 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JS-101 - Drug Profile
Product Description
Mechanism Of Action
JS-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lerociclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
milciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
NUV-422 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ON-108110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OQL-051 - Drug Profile
Product Description
Mechanism Of Action
History of Events
palbociclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-07220060 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRT-3645 - Drug Profile
Product Description
Mechanism Of Action
RGT-419B - Drug Profile
Product Description
Mechanism Of Action
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
History of Events
RMC-4550 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RP-13XXX - Drug Profile
Product Description
Mechanism Of Action
SCR-8079 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit CDK4/6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CDK4 for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDK4 for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
History of Events
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQ-05510 - Drug Profile
Product Description
Mechanism Of Action
TQB-3616 - Drug Profile
Product Description
Mechanism Of Action
History of Events
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
TVT-227 - Drug Profile
Product Description
Mechanism Of Action
TVT-243 - Drug Profile
Product Description
Mechanism Of Action
TVT-287 - Drug Profile
Product Description
Mechanism Of Action
TY-302 - Drug Profile
Product Description
Mechanism Of Action
voruciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XH-30002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2022: Drug combination shows effectiveness in patients with recurrent ER-positive endometrial cancer
Mar 10, 2022: NEJM publication of Novartis Kisqali data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Mar 10, 2022: EMA recommends extension of therapeutic indications for Abemaciclib
Mar 08, 2022: OnQuality Pharmaceuticals to present preclinical data for OQL-051, a novel chemotherapy-induced diarrhea therapeutic, at AACR
Mar 08, 2022: Lilly announces to present data from Verzenio at 2022 American Association for Cancer Research (AACR)
Feb 24, 2022: Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
Jan 27, 2022: Health Canada authorizes Verzenio (abemaciclib) as the first and only CDK4/6 inhibitor for patients with HR+ HER2- high risk early breast cancer
Jan 19, 2022: Shanghai Fosun Pharmaceutical: Announcement in relation to the progress of drug clinical trial by a subsidiary
Jan 03, 2022: Hengrui Medicine's class 1 new drug Isethionate Dalsili Tablets approved for marketing
Dec 28, 2021: Regor Therapeutics announces U.S. FDA authorization to conduct Regor's first-in-human clinical trial with the next generation targeted inhibitor RGT-419B for oncology
Dec 22, 2021: Simcere Pharmaceutical Group: Voluntary announcement in relation to the inclusion of Trilaciclib for injection as a priority review drug by CDE
Dec 16, 2021: G1 Therapeutics announces expansion of COSELA (Trilaciclib) sales force
Dec 15, 2021: Nuvation Bio receives FDA Fast Track Designation for NUV-422 for the treatment of high-grade gliomas, including glioblastoma multiforme
Dec 13, 2021: Nuvation Bio announces FDA Clearance of investigational new drug application for NUV-422 for the Treatment of Prostate Cancer
Dec 09, 2021: ESMO: Two years of adjuvant Palbociclib added to endocrine therapy does not improve outcomes in early breast cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Indications, 2022 (Contd..4)
Number of Products under Development by Indications, 2022 (Contd..5)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Products under Development by Companies, 2022 (Contd..10)
Products under Development by Companies, 2022 (Contd..11)
Products under Development by Companies, 2022 (Contd..12)
Products under Development by Companies, 2022 (Contd..13)
Products under Development by Companies, 2022 (Contd..14)
Products under Development by Companies, 2022 (Contd..15)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by Beta Pharma Inc, 2022
Pipeline by Betta Pharmaceuticals Co Ltd, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by ESSA Pharma Inc, 2022
Pipeline by Fochon Pharmaceutical Ltd, 2022
Pipeline by G1 Therapeutics Inc, 2022
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
Pipeline by HEC Pharma Co Ltd, 2022
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pipeline by MEI Pharma Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Nuvation Bio Inc, 2022
Pipeline by Onconova Therapeutics Inc, 2022
Pipeline by OnQuality Pharmaceuticals LLC, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Prelude Therapeutics Inc, 2022
Pipeline by Qilu Regor Therapeutics Inc, 2022
Pipeline by Rhizen Pharmaceuticals SA, 2022
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Pipeline by Sanofi, 2022
Pipeline by SATT Conectus Alsace SAS, 2022
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2022
Pipeline by SignalRx Pharmaceuticals Inc, 2022
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Sino Biopharmaceutical Ltd, 2022
Pipeline by Tetranov International Inc, 2022
Pipeline by Tiziana Life Sciences Plc, 2022
Pipeline by Travecta Therapeutics Inc, 2022
Pipeline by ViroStatics SRL, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
